AAAAAA
Results:
1-12
|
Results: 12
Authors:
Rueffer, U
Breuer, K
Josting, A
Lathan, B
Sieber, M
Manzke, O
Grotenhermen, FJ
Tesch, H
Bredenfeld, H
Koch, P
Nisters-Backes, H
Wolf, J
Engert, A
Diehl, V
Citation: U. Rueffer et al., Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment, ANN ONCOL, 12(9), 2001, pp. 1307-1311
Authors:
Manzke, O
Russello, O
Leenen, C
Diehl, V
Bohlen, H
Berthold, F
Citation: O. Manzke et al., Immunotherapeutic strategies in neuroblastoma: Antitumoral activity of deglycosylated ricin A conjugated anti-CD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies, MED PED ONC, 36(1), 2001, pp. 185-189
Authors:
Manzke, O
Tesch, H
Borchmann, P
Wolf, J
Lackner, K
Gossmann, A
Diehl, V
Bohlen, H
Citation: O. Manzke et al., Locoregional treatment of low-grade B-cell lymphoma with CD3 x CD19 bispecific antibodies and CD28 costimulation: I. Clinical phase I evaluation, INT J CANC, 91(4), 2001, pp. 508-515
Authors:
Manzke, O
Tesch, H
Lorenzen, J
Diehl, V
Bohlen, H
Citation: O. Manzke et al., Locoregional treatment of low-grade B-cell lymphoma with CD3 x CD19 bispecific antibodies and CD28 costimulation: II. Assessment of cellular immune responses, INT J CANC, 91(4), 2001, pp. 516-522
Authors:
Tesch, H
Engert, A
Manzke, O
Diehl, V
Bohlen, H
Citation: H. Tesch et al., Treatment of patients with malignant lymphomas with monoclonal antibodies, BONE MAR TR, 25, 2000, pp. S50-S53
Authors:
Titzer, S
Christensen, O
Manzke, O
Tesch, H
Wolf, J
Emmerich, B
Carsten, C
Diehl, V
Bohlen, H
Citation: S. Titzer et al., Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects, BR J HAEM, 108(4), 2000, pp. 805-816
Authors:
Tesch, H
Engert, A
Manzke, O
Diehl, V
Schnell, R
Bohlen, H
Citation: H. Tesch et al., Monoclonal antibody therapy of patients with non-Hodgkin's lymphomas, ONKOLOGIE, 22(1), 1999, pp. 18-24
Authors:
Manzke, O
Fitzgerald, KJ
Holliger, P
Klock, J
Span, M
Fleischmann, B
Hescheler, J
Liu, QH
Johnson, KS
Diehl, V
Hoogenboom, HR
Bohlen, H
Citation: O. Manzke et al., CD3x anti-nitrophenyl bispecific diabodies: Universal immunotherapeutic tools for retargeting T cells to tumors, INT J CANC, 82(5), 1999, pp. 700-708
Authors:
Manzke, O
Berthold, F
Huebel, K
Tesch, H
Diehl, V
Bohlen, H
Citation: O. Manzke et al., CD3xCD19 bispecific antibodies and CD28 bivalent antibodies enhance T-cellreactivity against autologous leukemic cells in pediatric B-all bone marrow, INT J CANC, 80(5), 1999, pp. 715-722
Authors:
Holliger, P
Manzke, O
Span, M
Hawkins, R
Fleischmann, B
Liu, QH
Wolf, J
Diehl, V
Cochet, O
Winter, G
Bohlen, H
Citation: P. Holliger et al., Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins, CANCER RES, 59(12), 1999, pp. 2909-2916
Authors:
Winkler, U
Jensen, M
Manzke, O
Schulz, H
Diehl, V
Engert, A
Citation: U. Winkler et al., Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an Anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8), BLOOD, 94(7), 1999, pp. 2217-2224
Authors:
Kolossov, E
Fleischmann, BK
Liu, Q
Bloch, W
Viatchenko-Karpinski, S
Manzke, O
Ji, GJ
Bohlen, H
Addicks, K
Hescheler, J
Citation: E. Kolossov et al., Functional characteristics of ES cell-derived cardiac precursor cells identified by tissue-specific expression of the green fluorescent protein, J CELL BIOL, 143(7), 1998, pp. 2045-2056
Risultati:
1-12
|